← Evidence map

TrialCancer medicine2026

Nanoparticle Albumin-Bound Paclitaxel and Nivolumab for PD-1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma.

Douglas Adkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

2 papers cite it

2026

this papertrialcites it

Nanoparticle Albumin-Bound Paclitaxel and Nivolumab for PD-1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma. | OpenQuestion